Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q71SY5
UPID:
MED25_HUMAN
Alternative names:
Activator interaction domain-containing protein 1; Activator-recruited cofactor 92 kDa component; Mediator complex subunit 25; p78
Alternative UPACC:
Q71SY5; A8K095; B9TX30; O95783; Q6P143; Q6QMH5; Q707U4; Q8TB55; Q9H0L5; Q9HB34
Background:
Mediator of RNA polymerase II transcription subunit 25, also known as Mediator complex subunit 25, plays a pivotal role in the regulated transcription of nearly all RNA polymerase II-dependent genes. It acts as a bridge, conveying information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. This protein is essential for RARA/RXRA-mediated transcription, highlighting its significance in gene expression regulation.
Therapeutic significance:
The protein's involvement in Charcot-Marie-Tooth disease, axonal, 2B2, and Basel-Vanagaite-Smirin-Yosef syndrome, diseases characterized by a range of neurological and developmental abnormalities, underscores its potential as a target for therapeutic intervention. Understanding the role of Mediator of RNA polymerase II transcription subunit 25 could open doors to potential therapeutic strategies.